News Medical

Hydroxychloroquine drug fails to reduce mild-moderate pain from primary hand osteoarthritis

The results of an interventional trial presented today at the European League Against Rheumatism Annual Congress (EULAR 2015) showed that use of the disease-modifying anti-rheumatic drug ...
Morningstar

Algia Pharma Gains FDA Support to Advance Novel Non-Opioid Pain Treatment Toward a Phase 2 Clinical Trial After IND-Enabling Studies With Indication Expanded to All Mild-to ...

Positive feedback from FDA suggests an indication from perioperative pain to all mild-to-moderate acute pain, significantly expanding clinical and commercial potential IND-enabling studies currently ...

Scientists design artificial pain receptor that senses pain intensity and self-heals

All over the body are tiny sensors called nociceptors whose job is to spot potentially harmful stimuli and send warning ...
Interesting Engineering on MSN

New self-healing artificial 'pain nerves' could give humanoid robots human-like reflexes

Researchers from China’s Northeast Normal University have developed a novel soft, jelly-like electronic “pain ...
Nanowerk

Self-healing pain sensor made from gelatin could give robots human-like reflexes

A gelatin memristor with 16 stable conductance states mimics biological pain perception, rating intensity, sensitizing after ...
Business Wire

Algia Pharma Gains FDA Support to Advance Novel Non-Opioid Pain Treatment Toward a Phase 2 Clinical Trial After IND-Enabling Studies With Indication Expanded to All Mild-to ...

BOCA RATON, Fla.--(BUSINESS WIRE)--Algia Pharma, LLC (“Algia”) today announced the company has received support from the U.S. Food and Drug Administration (FDA) to advance AlgiaPak ® toward a Phase 2 ...